Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
7.69 (1y: +20%)
Market Cap 1.05 B P/E(ttm) 5.10
Enterprise Value 1.21 B P/B
PDLI- NAS (USA)
PDL BioPharma, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$7.69
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.48
PDLI's Cash to Debt is ranked higher than
58% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. PDLI: 0.48 )
PDLI' s 10-Year Cash to Debt Range
Min: 0.29   Max: 4.14
Current: 0.48
0.29
4.14
Equity to Asset -0.243
PDLI's Equity to Asset is ranked lower than
61% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. PDLI: -0.243 )
PDLI' s 10-Year Equity to Asset Range
Min: -1.85   Max: 0.9
Current: -0.24
-1.85
0.9
Interest Coverage 15.9
PDLI's Interest Coverage is ranked higher than
74% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PDLI: 15.9 )
PDLI' s 10-Year Interest Coverage Range
Min: 5   Max: No Debt
Current: 15.9
F-Score: 7
Z-Score: 7.74
M-Score: -2.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 93.20
PDLI's Operating margin (%) is ranked higher than
100% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. PDLI: 93.20 )
PDLI' s 10-Year Operating margin (%) Range
Min: -194.4   Max: 94.9
Current: 93.2
-194.4
94.9
Net-margin (%) 56.5
PDLI's Net-margin (%) is ranked higher than
98% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. PDLI: 56.5 )
PDLI' s 10-Year Net-margin (%) Range
Min: -194.7   Max: 59.6
Current: 56.5
-194.7
59.6
ROA (%) 75.6
PDLI's ROA (%) is ranked higher than
100% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. PDLI: 75.6 )
PDLI' s 10-Year ROA (%) Range
Min: -17.5   Max: 75.6
Current: 75.6
-17.5
75.6
ROC (Joel Greenblatt) (%) 1461.60
PDLI's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PDLI: 1461.60 )
PDLI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -97.2   Max: 4023.3
Current: 1461.6
-97.2
4023.3
Revenue Growth (%) 10.3
PDLI's Revenue Growth (%) is ranked higher than
90% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PDLI: 10.3 )
PDLI' s 10-Year Revenue Growth (%) Range
Min: -17   Max: 50.7
Current: 10.3
-17
50.7
EBITDA Growth (%) 10.2
PDLI's EBITDA Growth (%) is ranked higher than
93% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PDLI: 10.2 )
PDLI' s 10-Year EBITDA Growth (%) Range
Min: -21.5   Max: 81.1
Current: 10.2
-21.5
81.1
EPS Growth (%) 7.9
PDLI's EPS Growth (%) is ranked higher than
92% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PDLI: 7.9 )
PDLI' s 10-Year EPS Growth (%) Range
Min: -24.7   Max: 77.8
Current: 7.9
-24.7
77.8
» PDLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

PDLI Guru Trades in Q2 2012

Joel Greenblatt 283,532 sh (+4.88%)
John Hussman 905,000 sh (unchged)
Jean-Marie Eveillard 2,800 sh (unchged)
Steven Cohen Sold Out
Jim Simons 11,379,554 sh (-2.2%)
Paul Tudor Jones 30,600 sh (-62.32%)
Jeremy Grantham 47,500 sh (-63.35%)
» More
Q3 2012

PDLI Guru Trades in Q3 2012

John Hussman 2,506,000 sh (+176.91%)
Paul Tudor Jones 53,900 sh (+76.14%)
Jim Simons 11,851,054 sh (+4.14%)
Jeremy Grantham 47,500 sh (unchged)
Jean-Marie Eveillard 2,800 sh (unchged)
Joel Greenblatt 261,241 sh (-7.86%)
» More
Q4 2012

PDLI Guru Trades in Q4 2012

Joel Greenblatt 1,729,133 sh (+561.89%)
Paul Tudor Jones 95,100 sh (+76.44%)
John Hussman 3,012,000 sh (+20.19%)
Jean-Marie Eveillard 2,800 sh (unchged)
Jeremy Grantham 40,800 sh (unchged)
Jim Simons 11,227,654 sh (-5.26%)
» More
Q1 2013

PDLI Guru Trades in Q1 2013

Jeremy Grantham 65,781 sh (+61.23%)
Joel Greenblatt 2,135,460 sh (+23.5%)
Jim Simons 12,277,098 sh (+9.35%)
Paul Tudor Jones 97,600 sh (+2.63%)
John Hussman 3,020,000 sh (+0.27%)
Jean-Marie Eveillard 2,800 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PDLI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Add 23.5%0.15%$6.65 - $7.53 $ 7.699%2135460
Joel Greenblatt 2012-12-31 Add 561.89%0.59%$7.09 - $8.37 $ 7.69-1%1729133
John Hussman 2012-12-31 Add 20.19%0.09%$7.09 - $8.37 $ 7.69-1%3012000
John Hussman 2012-09-30 Add 176.91%0.29%$6.59 - $7.73 $ 7.698%2506000
Seth Klarman 2012-03-31 Sold Out 1.5%$6.02 - $6.58 $ 7.6930%0
Joel Greenblatt 2012-03-31 Add 33.54%0.04%$6.02 - $6.58 $ 7.6930%270346
Seth Klarman 2011-12-31 Reduce -48.84%1.4%$5.35 - $6.4 $ 7.6929%8000000
Joel Greenblatt 2011-12-31 Add 31.29%0.04%$5.35 - $6.4 $ 7.6929%202444
George Soros 2011-12-31 Sold Out 0.001%$5.35 - $6.4 $ 7.6929%0
Seth Klarman 2011-09-30 Add 68.81%1.17%$5.47 - $6.39 $ 7.6930%15636000
John Hussman 2011-09-30 New Buy0.08%$5.47 - $6.39 $ 7.6930%905000
Joel Greenblatt 2011-09-30 Add 41.81%0.04%$5.47 - $6.39 $ 7.6930%154201
George Soros 2011-09-30 New Buy$5.47 - $6.39 $ 7.6930%10000
George Soros 2011-06-30 Sold Out $5.74 - $6.64 $ 7.6923%0
Seth Klarman 2011-03-31 Add 87.3%1.6%$4.69 - $6.36 $ 7.6943%10495225
Joel Greenblatt 2011-03-31 Add 128.09%0.12%$4.69 - $6.36 $ 7.6943%126863
George Soros 2011-03-31 New Buy$4.69 - $6.36 $ 7.6943%16700
Jean-Marie Eveillard 2011-03-31 Reduce -99.92%$4.69 - $6.36 $ 7.6943%2800
Seth Klarman 2010-12-31 New Buy2.01%$5.15 - $6.51 $ 7.6934%5603400
Joel Greenblatt 2010-12-31 New Buy0.11%$5.15 - $6.51 $ 7.6934%55620
Jean-Marie Eveillard 2010-09-30 Add 47.36%0.04%$5.135 - $6.63 $ 7.6934%3345040
David Dreman 2010-06-30 Sold Out 0.05%$5.05 - $6.57 $ 7.6931%0
George Soros 2010-06-30 Sold Out $5.05 - $6.57 $ 7.6931%0
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/E(ttm) 5.10
PDLI's P/E(ttm) is ranked higher than
95% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 26.90 vs. PDLI: 5.10 )
PDLI' s 10-Year P/E(ttm) Range
Min: 4.47   Max: 1079.48
Current: 5.1
4.47
1079.48
P/S 3.00
PDLI's P/S is ranked higher than
84% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. PDLI: 3.00 )
PDLI' s 10-Year P/S Range
Min: 2.49   Max: 111.95
Current: 3
2.49
111.95
PFCF 4.70
PDLI's PFCF is ranked higher than
94% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 27.82 vs. PDLI: 4.70 )
PDLI' s 10-Year PFCF Range
Min: 4.06   Max: 1241.47
Current: 4.7
4.06
1241.47
EV-to-EBIT 3.3
PDLI's EV-to-EBIT is ranked higher than
96% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. PDLI: 3.3 )
PDLI' s 10-Year EV-to-EBIT Range
Min: 2.9   Max: 300.1
Current: 3.3
2.9
300.1
PEG 0.5
PDLI's PEG is ranked higher than
93% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 1.80 vs. PDLI: 0.5 )
PDLI' s 10-Year PEG Range
Min: 0.19   Max: 0.5
Current: 0.5
0.19
0.5
Shiller P/E 8.7
PDLI's Shiller P/E is ranked lower than
100% of the Companies
in the Global Biotechnology industry.

( Industry Median: vs. PDLI: 8.7 )
PDLI' s 10-Year Shiller P/E Range
Min: 7.99   Max: 331.5
Current: 8.7
7.99
331.5

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 7.80
PDLI's Dividend Yield is ranked higher than
100% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PDLI: 7.80 )
PDLI' s 10-Year Dividend Yield Range
Min: 2.26   Max: 9.98
Current: 7.8
2.26
9.98
Dividend Payout 0.3964
PDLI's Dividend Payout is ranked higher than
60% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. PDLI: 0.3964 )
PDLI' s 10-Year Dividend Payout Range
Min: 0.42   Max: 0.53
Current: 0.4
0.42
0.53
Yield on cost (5-Year) 7.80
PDLI's Yield on cost (5-Year) is ranked higher than
99% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PDLI: 7.80 )
PDLI' s 10-Year Yield on cost (5-Year) Range
Min: 2.26   Max: 9.98
Current: 7.8
2.26
9.98
Share Buyback Rate 5.6
PDLI's Share Buyback Rate is ranked higher than
99% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -0.60 vs. PDLI: 5.6 )
PDLI' s 10-Year Share Buyback Rate Range
Min: 5.6   Max: -12.9
Current: 5.6

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 256.3
PDLI's Price/Net Current Asset Value is ranked lower than
53% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: 45.80 vs. PDLI: 256.3 )
PDLI' s 10-Year Price/Net Current Asset Value Range
Min: 47   Max: 1469.2
Current: 256.3
47
1469.2
Price/DCF (Projected) 0.9
PDLI's Price/DCF (Projected) is ranked higher than
94% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. PDLI: 0.9 )
PDLI' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 3.9
Current: 0.9
0.8
3.9
Price/Median PS Value 0.5
PDLI's Price/Median PS Value is ranked higher than
93% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. PDLI: 0.5 )
PDLI' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 11
Current: 0.5
0.4
11
Price/Peter Lynch Fair Value 0.3
PDLI's Price/Peter Lynch Fair Value is ranked higher than
98% of the 59 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. PDLI: 0.3 )
PDLI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.2   Max: 0.5
Current: 0.3
0.2
0.5
Earnings Yield (Greenblatt) 30.20
PDLI's Earnings Yield (Greenblatt) is ranked higher than
95% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PDLI: 30.20 )
PDLI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 35
Current: 30.2
0.3
35
Forward Rate of Return (Yacktman) 26.07
PDLI's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PDLI: 26.07 )
PDLI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.5   Max: 36.2
Current: 26.07
-9.5
36.2

Business Description

PDL BioPharma, Inc was organized as a Delaware corporation in 1986 under the name Protein Design Labs, Inc. In 2006, the Company changed its name to PDL BioPharma, Inc. The Company is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. The Company focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. It receives royalties based on sales of humanized antibody products marketed today and may also receive royalty payments on additional humanized antibody products launched before final patent expiry in December 2014. Under most of its licensing agreements, the Company is entitled to receive a flat-rate or tiered royalty based upon its licensees' net sales of covered antibodies. The Company has also entered into licensing agreements under which its have licensed certain rights for development stage products that have not yet reached commercialization including products that are currently in Phase 3 clinical trials. The Company has issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers as Queen et al. patents. The Company's licensees are subject to stringent regulation with respect to product safety and efficacy by various international, federal, state and local authorities.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:PDL.Germany
» More Articles for PDLI

Headlines

Articles On GuruFocus.com
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
comment on PDLI May 12 2013 
My 4 Favorites From The 20 Cheapest Healthcare Dividend Stock List May 02 2013 
FV 22 MSN 10 Apr 19 2013 
68 Top-Yielding Stocks with Ex-Dividend Date in March 2013 Feb 27 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
comment on PDLI Nov 13 2012 
Seth Klarman’s Investment Framework Sep 15 2012 
A Look at Two Undervalued Small-Cap Health Care Stocks Aug 09 2012 
Why Should You Invest Only in High-Quality Companies? Jun 13 2012 

More From Our Partners
PDL BioPharma Guides Higher 2Q Royalties - Analyst Blog Jun 13 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK